Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on April 28, 2025
LifeMD Acquires Women’s Health Provider Optimal Human Health MD to Accelerate Entry into the Women’s Health Market
GlobeNewswire
·
April 28, 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the acquisition of key assets from Optimal Human Health MD (“Optimal”), a nationwide women’s health virtual care …
IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025
GlobeNewswire
·
April 28, 2025
First gamma-delta (γδ) TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative to conventional CD3-based approaches without significant adverse events such as cytokine release syndrome (CRS) INB-600 TCE …
Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial
GlobeNewswire
·
April 28, 2025
NEWPORT BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), is proud to announce that Co-Founder Deniel Mero was recently …
DLH to Announce Fiscal 2025 Second Quarter Financial Results
GlobeNewswire
·
April 28, 2025
ATLANTA, April 28, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital transformation and cyber security solutions to …
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
GlobeNewswire
·
April 28, 2025
- Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, …
Impulse Dynamics®’ INTEGRA-D Trial Completes Efficacy Phase
GlobeNewswire
·
April 28, 2025
Marlton, NJ, April 28, 2025 (GLOBE NEWSWIRE) -- Impulse Dynamics® plc, a global medical device company dedicated to improving the lives of people with heart failure (HF), is proud to announce that it reached an important milestone in the INTEGRA-D™ …
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
GlobeNewswire
·
April 28, 2025
New Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated with Dose-Dependent and Significant Improvements in Multiple Inflammatory and Fibrotic Biomarkers Further Confirms the Clinical Potential of Nebokitug As a …
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.
GlobeNewswire
·
April 28, 2025
Acquisition of approximately 71% stake in Kokomodo Ltd. Acquisition uniquely combines Pluri's mass-scale cell production expertise with Kokomodo Ltd.’s ability to craft real, controlled, climate-resilient cacao using cellular agriculture technology HAIFA, …
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting
GlobeNewswire
·
April 28, 2025
New data includes real-world analyses of VOQUEZNA-treated patients in the U.S. diagnosed with gastroesophageal reflux disease (GERD) FLORHAM PARK, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical …
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug
GlobeNewswire
·
April 28, 2025
SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent …
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™
GlobeNewswire
·
April 28, 2025
New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZ New subject matter listed in the U.S. Food and Drug Administration’s (“FDA”) Orange Book HALIFAX …
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
GlobeNewswire
·
April 28, 2025
MELBOURNE, Australia and SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative …
Veri Medtech (VRHI) Retains PCAOB Auditor
GlobeNewswire
·
April 28, 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Veri Medtech Holdings, Inc. (OTC Markets: (“VRHI”) ("Veri Medtech") announced today that it has retained Salberg …
Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST
GlobeNewswire
·
April 28, 2025
– Phase 1 dose-escalation study to evaluate ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure – – Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive and …
Crescent Biopharma Appoints David Lubner to Board of Directors
GlobeNewswire
·
April 28, 2025
Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnology company developing novel precision-engineered molecules …
BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development
GlobeNewswire
·
April 28, 2025
Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very heavily pretreated patients Clinical benefit observed in 83% of evaluable patient sub-group treated with the phase 3 formulation Improved new Bria …
ElevateBio Announces Transition of David Hallal to Executive Chairman of the Board of Directors
GlobeNewswire
·
April 28, 2025
WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- ElevateBio, a technology-driven company focused on powering the creation of life-transforming genetic medicines, announced that David Hallal will transition from Chairman and CEO to Executive Chairman of …
Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
GlobeNewswire
·
April 28, 2025
Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patients who face cycles of relapse and remission TARRYTOWN, …
Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting
GlobeNewswire
·
April 28, 2025
Compelling Phase 1 safety and efficacy data for FAP-Dox (AVA6000) with preliminary evidence of efficacy in salivary gland cancers and no severe cardiac toxicity Progression free survival (PFS) data to date represents a near doubling of the benchmarking …
BPGbio CEO Dr. Niven R. Narain Named to The Medicine Maker Power List 2025
GlobeNewswire
·
April 28, 2025
BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered clinical-stage biopharma company, today announced that President and CEO Niven R. Narain, Ph.D. has been named to The Medicine Maker’s Power List 2025. The annual list …